Trial Profile
An Open-Label Study to Assess the Safety, Tolerability, and Efficacy of Active Immunotherapy With Dose Escalation and Cohort Expansion of OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal, or Breast Cancer Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs OBI 833 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Lung cancer; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors OBI Pharma
- 22 Apr 2021 Status changed from recruiting to completed.
- 19 Nov 2020 According to an OBI Pharma media release, data from this study will be presented at the European Society of Clinical Oncology Asia (ESMO Asia) 2020 Virtual Scientific Program from November 20-22, 2020.
- 19 Nov 2020 Results published in the OBI Pharma Media Release